Results 41 to 50 of about 37,664 (239)
Journal of Clinical and Translational Hepatology, 2023 Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer for which effective therapeutic agents are lacking. Fibroblast growth factor receptor 2 (FGFR2) has become a promising therapeutic target in ICC; however, its ...
Yining Zou +8 more
semanticscholar +1 more source
ACS Medicinal Chemistry Letters, 2023 Fibroblast growth factor receptors (FGFRs) are transmembrane receptor tyrosine kinases that regulate multiple physiological processes. Aberrant activation of FGFR2 and FGFR3 has been linked to the pathogenesis of many tumor types, including ...
Minh-Hai Nguyen +25 more
semanticscholar +1 more source
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review)
International Journal of Molecular Medicine, 2009 FGFR2 gene at human chromosome 10q26 encodes FGFR2b and FGFR2c isoforms functioning as FGF receptors with distinct expression domain and ligand specificity. FGFR2 plays oncogenic and anti-oncogenic roles in a context-dependent manner. Single nucleotide polymorphisms (SNPs) within intron 2 of FGFR2 gene are associated with breast cancer through allelic ...
Yuriko, Katoh, Masaru, Katoh
openaire +3 more sources
FGFR2 amplification in colorectal adenocarcinoma [PDF]
Molecular Case Studies, 2017 FGFR2 is recurrently amplified in 5% of gastric cancers and 1%–4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell ...
Carter, Jamal H +6 more
openaire +3 more sources
Nature Communications, 2023 Exocrine acinar cells in salivary glands (SG) are critical for oral health and loss of functional acinar cells is a major clinical challenge. Fibroblast growth factor receptors (FGFR) are essential for early development of multiple organs, including SG ...
M. Aure +6 more
semanticscholar +1 more source
FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival. [PDF]
PLoS ONE, 2014 Aberrant kinase activation resulting from mutation, amplification, or translocation can drive growth and survival in a subset of human cancer. FGFR2 is amplified in breast and gastric cancer, and we report here the first characterization of FGFR2 gene ...
Anjili Mathur +5 more
doaj +1 more source
Cancer Discovery, 2022 FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or to other less defined mechanisms ...
Qibiao Wu +22 more
semanticscholar +1 more source
British Journal of Cancer, 2022 Background Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a dismal prognosis. Recently, several actionable genetic aberrations were identified with significant enrichment in intrahepatic CCA, including FGFR2 gene fusions with ...
O. Neumann +21 more
semanticscholar +1 more source
Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway
Cells, 2019 Tight regulation of signaling from receptor tyrosine kinases is required for normal cellular functions and uncontrolled signaling can lead to cancer. Fibroblast growth factor receptor 2 (FGFR2) is a receptor tyrosine kinase that induces proliferation and
Patrycja Szybowska +4 more
doaj +1 more source
Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer
Biomedicines, 2023 Background: c-mesenchymal epithelial transition factor receptor (c-MET) and fibroblast growth factor receptor 2 (FGFR2) amplification have been identified as factors associated with advanced stage and poor prognosis in gastric cancer (GC). While they are
Seonggyu Byeon +4 more
doaj +1 more source